High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland

被引:49
作者
Brozek, Izabela [1 ,3 ]
Ochman, Karolina [1 ]
Debniak, Jaroslaw [2 ]
Morzuch, Lucyna [1 ,4 ]
Ratajska, Magdalena [1 ]
Stepnowska, Magdalena [1 ]
Stukan, Maciej [2 ]
Emerich, Janusz [2 ]
Limon, Janusz [1 ,3 ]
机构
[1] Med Univ Gdansk, Dept Biol & Genet, PL-80211 Gdansk, Poland
[2] Med Univ Gdansk, Dept Gynecol, PL-80211 Gdansk, Poland
[3] Reg Oncol Ctr Gdansk, Gdansk, Poland
[4] Univ Gdansk, Fac Biol Geog & Oceanol, PL-80952 Gdansk, Poland
关键词
BRCA1; BRCA2; mutations; ovarian cancer; hereditary;
D O I
10.1016/j.ygyno.2007.09.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. We estimated the prevalence of BRCA1/2 germline mutations in consecutive ovarian cancers and con-elated the mutation status with clinicopathological features. Methods. 151 consecutive primary ovarian cancer patients were screened for BRCA1/2 germline mutations. Results. We identified BRCA1/2 germline mutations in 21 (13.9%) patients. Seventeen (81%) of carriers have BRCA1 and four (19%) have BRCA2 mutation. BRCA1/2 carriers have a distinctly longer overall survival than sporadic cases (log-rank, p=0.014). Conclusions. The relatively high proportion of BRCA1/2 carriers among unselected ovarian cancer patients indicates the necessity of searching for recurrent BRCA mutations in each case of ovarian carcinoma. This routine screen should be widened to include denaturing high performance liquid chromatography (DHPLC) analysis of both exons 11 of BRCA1 and BRCA2 genes in women with positive family history. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:433 / 437
页数:5
相关论文
共 31 条
[1]  
Aida H, 1998, CLIN CANCER RES, V4, P235
[2]  
*ASCO, 1996, J CLIN ONCOL, V14, P1737
[3]   Effect of BRCA mutations on the length of survival in epithelial ovarian tumors [J].
Ben David, Y ;
Chetrit, A ;
Hirsh-Yechezkel, G ;
Friedman, E ;
Beck, BD ;
Beller, U ;
Ben-Baruch, G ;
Fishman, A ;
Levavi, H ;
Lubin, F ;
Menczer, J ;
Piura, B ;
Struewing, JP ;
Modan, B .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :463-466
[4]  
Berchuck A, 1998, CLIN CANCER RES, V4, P2433
[5]   Improved survival in women with BRCA-associated ovarian carcinoma [J].
Cass, I ;
Baldwin, RL ;
Varkey, T ;
Moslehi, R ;
Narod, SA ;
Karlan, BY .
CANCER, 2003, 97 (09) :2187-2195
[6]  
Geisler JP, 2002, JNCI-J NATL CANCER I, V94, P61
[7]   High incidence of 4153delA BRCA1 gene mutations in Lithuanian breast- and breast-ovarian cancer families [J].
Gronwald, J ;
Elsakov, P ;
Górski, B ;
Lubinski, J .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 (02) :111-113
[8]  
Grudinina N. A., 2005, Genetika, V41, P405
[9]  
Grzybowska E, 2002, ACTA BIOCHIM POL, V49, P351
[10]   Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel [J].
Hirsh-Yechezkel, G ;
Chetrit, A ;
Lubin, F ;
Friedman, E ;
Peretz, T ;
Gershoni, R ;
Rizel, S ;
Struewing, JP ;
Modan, B .
GYNECOLOGIC ONCOLOGY, 2003, 89 (03) :494-498